About Acorda Therapeutics (NASDAQ:ACOR)
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300
Debt
Debt-to-Equity Ratio0.64%
Current Ratio3.07%
Quick Ratio2.81%
Price-To-Earnings
Trailing P/E Ratio21.51
Forward P/E Ratio-24.28
P/E GrowthN/A
Sales & Book Value
Annual Sales$588.29 million
Price / Sales1.82
Cash Flow$1.7407 per share
Price / Cash13.11
Book Value$11.12 per share
Price / Book2.05
Profitability
EPS (Most Recent Fiscal Year)$1.04
Net Income$-223,350,000.00
Net Margins-37.97%
Return on Equity-4.88%
Return on Assets-2.41%
Miscellaneous
Employees484
Outstanding Shares46,910,000
Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How were Acorda Therapeutics' earnings last quarter?
Acorda Therapeutics (NASDAQ:ACOR) posted its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.88 by $0.27. The biopharmaceutical company earned $188.40 million during the quarter, compared to analyst estimates of $171.70 million. Acorda Therapeutics had a negative return on equity of 4.88% and a negative net margin of 37.97%. The company's quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.05 earnings per share. View Acorda Therapeutics' Earnings History.
When is Acorda Therapeutics' next earnings date?
What price target have analysts set for ACOR?
13 equities research analysts have issued 12-month price targets for Acorda Therapeutics' stock. Their predictions range from $13.00 to $37.00. On average, they anticipate Acorda Therapeutics' share price to reach $21.8333 in the next twelve months. View Analyst Ratings for Acorda Therapeutics.
What are Wall Street analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
- 1. According to Zacks Investment Research, "Acorda is presently working on strengthening its Parkinson’s pipeline by focusing on the late stage candidate Inbrija in its portfolio. The FDA accepted Inbrija’s new drug application in February 2018. The company’s share price has outperformed the industry so far this year. However, the company’s key multiple sclerosis drug Ampyra is expected to face generic competition from mid-2018 in the United States. Hence, Acorda’s dependence on Ampyra to draw major part of its revenues is concerning. Moreover, Inbrija received a refusal-to-file letter from the FDA in August last year. This delayed its expected commercial launch which was anticipated much earlier. Estimates have been stable lately ahead of the company’s Q1 earnings release. The company has negative record of earnings surprises in recent quarters." (4/24/2018)
- 2. HC Wainwright analysts commented, "Ziopharm’s CAR-T Programs Make a Splash at ASH; Reiterate Buy Ziopharm’s 2nd-gen CAR-T shows promise in early study. We attended the 2017 Annual Meeting of the American Society of Hematology (ASH) over the last weekend, where Ziopharm presented interim results from the ongoing Phase 1 clinical study in patients with CD19 + leukemia or lymphoma treated with Ziopharm’s second generation CD19 + CAR-T therapy. Recall, Ziopharm’s second generation CAR-T cells were manufactured using the company’s proprietary Sleeping Beauty (SB) transposon platform which shortens the manufacturing process to two weeks compared to the typical 3-4 weeks for currently approved CAR-T therapies, such as Kymriah from Novartis (NVS; not rated) and Yescarta from Gilead (GILD; not rated). The results from the Phase 1 study show that treatment of patients with relapsed/refractory leukemia or lymphoma (n = 8) resulted in a 50% complete response rate after one month of therapy." (12/14/2017)
- 3. Cantor Fitzgerald analysts commented, "Not what ACOR stock needed. ACOR announced this morning that an increase in blood monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson’s disease (PD)." (11/15/2017)
Who are some of Acorda Therapeutics' key competitors?
Some companies that are related to Acorda Therapeutics include China Biologic Products (CBPO), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), Halozyme (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD) and DBV Technologies (DBVT).
Who are Acorda Therapeutics' key executives?
Acorda Therapeutics' management team includes the folowing people:
- Dr. Ron Cohen, Founder, CEO , Pres & Director (Age 62)
- Mr. David Lawrence, Chief of Bus. Operations & Principal Accounting Officer (Age 60)
- Ms. Jane Wasman, Pres of International, Gen. Counsel & Corp. Sec. (Age 62)
- Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 45)
- Dr. Burkhard Blank M.D., Chief Medical Officer (Age 63)
Has Acorda Therapeutics been receiving favorable news coverage?
News headlines about ACOR stock have trended somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acorda Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 48.27 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Acorda Therapeutics' major shareholders?
Acorda Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include
SCOPIA CAPITAL MANAGEMENT LP
(18.10%) and
SCOPIA CAPITAL MANAGEMENT LP
(18.10%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Jane Wasman, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.
How do I buy shares of Acorda Therapeutics?
Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acorda Therapeutics' stock price today?
One share of ACOR stock can currently be purchased for approximately $22.70.
How big of a company is Acorda Therapeutics?
Acorda Therapeutics has a market capitalization of $1.10 billion and generates $588.29 million in revenue each year. The biopharmaceutical company earns $-223,350,000.00 in net income (profit) each year or $1.04 on an earnings per share basis. Acorda Therapeutics employs 484 workers across the globe.
How can I contact Acorda Therapeutics?
Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.
MarketBeat Community Rating for Acorda Therapeutics (ACOR)
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Acorda Therapeutics (NASDAQ:ACOR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Acorda Therapeutics in the last 12 months. Their average twelve-month price target is $21.8333, suggesting that the stock has a possible downside of 4.32%. The high price target for ACOR is $37.00 and the low price target for ACOR is $13.00. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.15 | 2.15 | 2.00 | 2.11 |
| Ratings Breakdown: | 1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $21.8333 | $21.8333 | $20.3333 | $23.25 |
| Price Target Upside: | 4.32% downside | 9.59% downside | 18.83% downside | 12.76% downside |
Acorda Therapeutics (NASDAQ:ACOR) Consensus Price Target History
Acorda Therapeutics (NASDAQ:ACOR) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Acorda Therapeutics (NASDAQ:ACOR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Acorda Therapeutics (NASDAQ ACOR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.90%
Acorda Therapeutics (NASDAQ ACOR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/19/2018 | David Lawrence | Insider | Sell | 31,000 | $27.58 | $854,980.00 | 5,275 |  |
| 12/1/2017 | Burkhard Blank | Insider | Sell | 11,050 | $20.53 | $226,856.50 | 33,150 | |
| 10/9/2017 | David Lawrence | Insider | Sell | 250 | $25.40 | $6,350.00 | | |
| 8/29/2017 | Scopia Capital Management Lp | Major Shareholder | Buy | 766,201 | $19.23 | $14,734,045.23 | | |
| 8/1/2017 | Barry E Greene | Director | Sell | 10,000 | $21.57 | $215,700.00 | 10,000 | |
| 7/31/2017 | Lorin Randall | Director | Sell | 10,000 | $21.66 | $216,600.00 | 10,000 | |
| 6/16/2017 | Ron Cohen | Insider | Buy | 20,000 | $16.95 | $339,000.00 | 511,648 | |
| 5/15/2017 | Andrew A Hindman | Insider | Sell | 7,704 | $15.75 | $121,338.00 | 46,123 | |
| 12/14/2016 | Ron Cohen | Insider | Sell | 40,172 | $20.75 | $833,569.00 | 519,860 | |
| 10/21/2016 | Richard P Batycky | Insider | Sell | 2,063 | $20.30 | $41,878.90 | 45,916 | |
| 10/7/2016 | David Lawrence | Insider | Sell | 250 | $20.82 | $5,205.00 | 8,952 | |
| 10/3/2016 | Jane Wasman | Insider | Sell | 3,750 | $20.78 | $77,925.00 | 105,021 | |
| 9/23/2016 | Jane Wasman | Insider | Sell | 500 | $27.32 | $13,660.00 | 109,271 | |
| 6/22/2016 | David Lawrence | Insider | Sell | 500 | $25.09 | $12,545.00 | 9,702 | |
| 6/8/2016 | Steven M Rauscher | Director | Sell | 1,086 | $27.83 | $30,223.38 | 1,086 | |
| 5/13/2016 | Andrew A Hindman | Insider | Sell | 4,860 | $26.11 | $126,894.60 | 49,670 | |
| 4/19/2016 | Lorin Randall | Director | Sell | 1,488 | $28.68 | $42,675.84 | 1,488 | |
| 1/4/2016 | Ian F. Smith | Director | Sell | 13,231 | $41.85 | $553,717.35 | | |
| 12/23/2015 | Jane Wasman | insider | Sell | 10,751 | $43.10 | $463,368.10 | 100,124 | |
| 12/22/2015 | Lauren M. Sabella | insider | Sell | 7,113 | $42.04 | $299,030.52 | 14,378 | |
| 12/21/2015 | Jane Wasman | Insider | Sell | 817 | $42.00 | $34,314.00 | 108,579 | |
| 12/18/2015 | David Lawrence | insider | Sell | 39,026 | $40.63 | $1,585,626.38 | 9,202 | |
| 12/17/2015 | Lauren M. Sabella | insider | Sell | 14,229 | $40.00 | $569,160.00 | 14,378 | |
| 12/1/2015 | Enrique J Carrazana | Insider | Sell | 7,218 | $38.08 | $274,861.44 | 32,148 | |
| 12/1/2015 | Ron Cohen | CEO | Sell | 11,850 | $38.08 | $451,248.00 | 400,550 | |
| 10/19/2015 | Andrew Blight | insider | Sell | 32,500 | $30.87 | $1,003,275.00 | 71,659 | |
| 10/7/2015 | Michael W. Rogers | CFO | Sell | 5,700 | $30.24 | $172,368.00 | 41,677 | |
| 10/5/2015 | Jane Wasman | insider | Sell | 3,750 | $31.75 | $119,062.50 | 98,097 | |
| 10/5/2015 | Ron Cohen | CEO | Sell | 135,000 | $28.03 | $3,784,050.00 | 412,400 | |
| 9/21/2015 | Andrew Blight | insider | Sell | 13,085 | $31.30 | $409,560.50 | 71,659 | |
| 5/15/2015 | Andrew A Hindman | Insider | Sell | 4,779 | $29.82 | $142,509.78 | | |
| 1/12/2015 | Enrique J Carrazana | Insider | Sell | 97,993 | $42.21 | $4,136,284.53 | | |
| 12/18/2014 | David Lawrence | Insider | Sell | 27,109 | $40.11 | $1,087,341.99 | | |
| 12/18/2014 | John P Kelley | Director | Sell | 10,000 | $40.00 | $400,000.00 | | |
| 12/1/2014 | David Lawrence | Insider | Sell | 8,898 | $35.60 | $316,768.80 | | |
| 12/1/2014 | Lauren M Sabella | VP | Sell | 3,242 | $35.58 | $115,350.36 | | |
| 12/1/2014 | Michael W Rogers | CFO | Sell | 230 | $35.58 | $8,183.40 | | |
| 12/1/2014 | Ron Cohen | CEO | Sell | 34,394 | $35.59 | $1,224,082.46 | | |
| 10/7/2014 | Michael W Rogers | CFO | Sell | 5,700 | $33.10 | $188,670.00 | | |
| 10/3/2014 | Jane Wasman | Insider | Sell | 3,750 | $34.13 | $127,987.50 | | |
| 9/24/2014 | Jane Wasman | Insider | Sell | 14,923 | $36.00 | $537,228.00 | | |
| 8/27/2014 | Jane Wasman | Insider | Sell | 14,923 | $33.00 | $492,459.00 | | |
| 12/5/2013 | Lauren Sabella | VP | Sell | 8,797 | $31.81 | $279,832.57 | 12,403 | |
| 12/2/2013 | Enrique Carrazana | Insider | Sell | 1,640 | $33.56 | $55,038.40 | 32,527 | |
| 10/15/2013 | Enrique J Carrazana | Insider | Sell | 3,333 | $32.38 | $107,922.54 | | |
| 10/3/2013 | Jane Wasman | Insider | Sell | 3,750 | $35.74 | $134,025.00 | 105,459 | |
| 8/20/2013 | Ron Cohen | CEO | Sell | 149,000 | $34.10 | $5,080,900.00 | 478,868 | |
| 8/2/2013 | John Kelley | Director | Sell | 15,000 | $38.00 | $570,000.00 | | |
| 7/19/2013 | Andrew Blight | Insider | Sell | 19,296 | $37.82 | $729,774.72 | | |
| 6/10/2013 | Ron Cohen | CEO | Sell | 11,000 | $34.15 | $375,650.00 | | |
| 5/8/2013 | Sandra Phd Panem | Director | Sell | 10,000 | $33.80 | $338,000.00 | | |
| 12/4/2012 | Lauren M Sabella | VP | Sell | 4,364 | $24.58 | $107,267.12 | | |
| 12/3/2012 | Andrew Blight | Insider | Sell | 7,200 | $24.20 | $174,240.00 | | |
| 12/3/2012 | David Lawrence | CFO | Sell | 9,313 | $24.21 | $225,467.73 | | |
| 12/3/2012 | Ron Cohen | CEO | Sell | 16,407 | $24.22 | $397,377.54 | | |
| 11/13/2012 | Sandra Phd Panem | Director | Sell | 22,569 | $24.12 | $544,364.28 | | |
(Data available from 1/1/2013 forward)
Acorda Therapeutics (NASDAQ ACOR) News Headlines
| Source: |
|
Acorda Therapeutics (NASDAQ:ACOR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Acorda Therapeutics (NASDAQ:ACOR) Income Statement, Balance Sheet and Cash Flow Statement
Acorda Therapeutics (NASDAQ ACOR) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
